Q-omics provides the consensus-scored FA2H profile across patient tissues and cancer cell-line models. FA2H expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FA2H is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FA2H RNA expression shows 17,749 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where FA2H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FA2H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FA2H survival associations across molecular data types. FA2H RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FA2H RNA expression–survival associations across cancer types. High FA2H expression shows unfavorable associations in LUAD, MESO and KIRP, but favorable associations in HNSC, BLCA and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FA2H RNA expression.
This table summarizes FA2H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FA2H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FA2H shows lower tumor expression in KIRC and THCA and higher tumor expression in LUAD, UCEC, BRCA and CHOL. The KIRC box plot shows higher FA2H RNA expression in normal versus tumor tissue (log2 FC = −2.303, t-test p < 0.001).
This table shows molecular features associated with FA2H in patient tissues and cancer cell lines. In patient samples, FA2H shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FA2H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and PANCREAS.
